As VEGF-A is overexpressed in tumors and is associated with tumor progression, invasion, and metastasis, it represents the main target of anti-angiogenic drugs in cancer therapy, which are applied as VEGF-A and VEGFR2 inhibitors [100,101,102]. The gene discussed is VEGFA; the disease is neoplasm.